Free Trial
→ SpaceX eyes a 1.75 trillion valuation - here's what to know (From Brownstone Research) (Ad)tc pixel
NASDAQ:REPL

Replimune Group Q4 2026 Earnings Report

Replimune Group logo
$9.98 +1.11 (+12.51%)
Closing price 04:00 PM Eastern
Extended Trading
$9.89 -0.09 (-0.89%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Replimune Group EPS Results

Actual EPS
N/A
Consensus EPS
-$0.73
Beat/Miss
N/A
One Year Ago EPS
N/A

Replimune Group Revenue Results

Actual Revenue
N/A
Expected Revenue
$5.57 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Replimune Group Announcement Details

Quarter
Q4 2026
Date
6/4/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Replimune Group Earnings Headlines

Replimune Group, Inc.: Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology ...
June 1 at 10:12 PM  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68641671-replimune-group-inc-replimune-presents-final-first-in-human-data-for-rp2-in-advanced-solid-tumors-during-oral-presentation-at-the-2026-american-soc-399.htm
Replimune Group, Inc.: Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical ...
June 1 at 10:12 PM  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68641636-replimune-group-inc-replimune-presents-3-year-landmark-overall-survival-analysis-from-ignyte-clinical-trial-during-oral-presentation-at-the-2026-am-399.htm
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.tc pixel
June 3 at 1:00 AM  |  Brownstone Research (Ad)
Why Is REPL Stock Gaining In Pre-Market Today?
June 1 at 10:12 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/why-repl-stock-gaining-pre-105607137.html
Replimune Group Presents Final First-in-Human Data for RP2 Oncolytic Immunotherapy at ASCO 2026
May 31 at 8:11 AM  |  quiverquant.comQ
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
May 31 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/31/3303918/0/en/replimune-presents-final-first-in-human-data-for-rp2-in-advanced-solid-tumors-during-oral-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting.html
See More Replimune Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Replimune Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Replimune Group and other key companies, straight to your email.

About Replimune Group

Replimune Group (NASDAQ:REPL) is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation. The company’s pipeline also includes RP2, RP3 and RP4, each engineered with distinct cytokine or co‐stimulatory transgenes to address different tumor types and immune environments. Clinical studies to date have evaluated these candidates as monotherapies and in combination with checkpoint inhibitors, with initial data reported in melanoma, cutaneous squamous cell carcinoma and other solid tumors.

Founded in 2015 and headquartered in Woburn, Massachusetts, Replimune designs and executes clinical trials across North America and Europe. The company’s research and manufacturing infrastructure supports rapid development and scalable production of its viral immunotherapies. Replimune maintains collaborations with academic institutions and clinical research organizations to advance its programs through late-stage studies.

Replimune is led by an experienced management team and board of directors with deep expertise in oncology drug development, virology and regulatory affairs. The company’s leadership draws on years of precedent in advancing innovative cancer treatments from early discovery into pivotal clinical trials.

View Replimune Group Profile
Earnings Tools